{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=CVL-231",
    "query": {
      "intervention": "CVL-231"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 13,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=CVL-231&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-02T04:21:50.595Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05644977",
      "title": "A Multiple Dose Trial of Emraclidine in Elderly Participants and in Participants With Dementia Due to Alzheimer's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Participants",
        "Alzheimer's Disease Dementia"
      ],
      "interventions": [
        {
          "name": "Emraclidine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "55 Years to 90 Years"
      },
      "enrollment_count": 17,
      "start_date": "2022-12-02",
      "completion_date": "2025-04-14",
      "has_results": false,
      "last_update_posted_date": "2025-05-02",
      "last_synced_at": "2026-09-02T04:21:50.595Z",
      "location_count": 11,
      "location_summary": "Cypress, California • San Diego, California • Hialeah, Florida + 8 more",
      "locations": [
        {
          "city": "Cypress",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Hialeah",
          "state": "Florida"
        },
        {
          "city": "Decatur",
          "state": "Georgia"
        },
        {
          "city": "Honolulu",
          "state": "Hawaii"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05644977"
    },
    {
      "nct_id": "NCT05227703",
      "title": "A Trial of 15 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With Schizophrenia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Schizophrenia"
      ],
      "interventions": [
        {
          "name": "Emraclidine 15 mg",
          "type": "DRUG"
        },
        {
          "name": "Emraclidine 30 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 391,
      "start_date": "2022-07-05",
      "completion_date": "2024-09-11",
      "has_results": true,
      "last_update_posted_date": "2025-10-28",
      "last_synced_at": "2026-09-02T04:21:50.595Z",
      "location_count": 19,
      "location_summary": "Bentonville, Arkansas • Bellflower, California • La Habra, California + 15 more",
      "locations": [
        {
          "city": "Bentonville",
          "state": "Arkansas"
        },
        {
          "city": "Bellflower",
          "state": "California"
        },
        {
          "city": "La Habra",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Sherman Oaks",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05227703"
    },
    {
      "nct_id": "NCT06301971",
      "title": "A Study to Assess Mass Balance, Pharmacokinetics, Metabolism, and Excretion of Emraclidine in Healthy Adult Male Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Participants"
      ],
      "interventions": [
        {
          "name": "Emraclidine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cerevel Therapeutics, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "MALE",
        "summary": "18 Years to 55 Years · Male only"
      },
      "enrollment_count": 8,
      "start_date": "2024-03-04",
      "completion_date": "2024-04-04",
      "has_results": false,
      "last_update_posted_date": "2024-05-02",
      "last_synced_at": "2026-09-02T04:21:50.595Z",
      "location_count": 1,
      "location_summary": "Austin, Texas",
      "locations": [
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06301971"
    },
    {
      "nct_id": "NCT05106309",
      "title": "Pharmacokinetics of CVL-231 Following Single Oral Administration of Modified- and Immediate-release Formulations in Fasted and Fed Healthy Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Schizophrenia"
      ],
      "interventions": [
        {
          "name": "10 mg CVL-231 as IR formulation",
          "type": "DRUG"
        },
        {
          "name": "30 mg CVL-231 as slow-release MR formulation",
          "type": "DRUG"
        },
        {
          "name": "30 mg CVL-231 as medium release MR formulation",
          "type": "DRUG"
        },
        {
          "name": "30 mg CVL-231 as fast release MR formulation",
          "type": "DRUG"
        },
        {
          "name": "30 mg CVL-231 Target Release, Fasted",
          "type": "DRUG"
        },
        {
          "name": "30 mg CVL-231 Target Release, Fed",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cerevel Therapeutics, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 16,
      "start_date": "2021-12-29",
      "completion_date": "2022-02-24",
      "has_results": false,
      "last_update_posted_date": "2022-04-27",
      "last_synced_at": "2026-09-02T04:21:50.595Z",
      "location_count": 1,
      "location_summary": "Tempe, Arizona",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05106309"
    },
    {
      "nct_id": "NCT05227690",
      "title": "A Trial of 10 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With Schizophrenia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Schizophrenia"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Emraclidine 10 mg",
          "type": "DRUG"
        },
        {
          "name": "Emraclidine 30 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 385,
      "start_date": "2022-06-30",
      "completion_date": "2024-08-26",
      "has_results": true,
      "last_update_posted_date": "2025-09-17",
      "last_synced_at": "2026-09-02T04:21:50.595Z",
      "location_count": 21,
      "location_summary": "Little Rock, Arkansas • Anaheim, California • Garden Grove, California + 18 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Garden Grove",
          "state": "California"
        },
        {
          "city": "Lemon Grove",
          "state": "California"
        },
        {
          "city": "Montclair",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05227690"
    },
    {
      "nct_id": "NCT05933187",
      "title": "A Study Evaluating the Pharmacokinetics and Relative Bioavailability of Emraclidine Immediate-Release Tablets in Healthy Adult Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Participants"
      ],
      "interventions": [
        {
          "name": "Treatment A: Emraclidine 30mg IR tablets (reference)",
          "type": "DRUG"
        },
        {
          "name": "Treatment B: Emraclidine 30mg IR test tablets 1",
          "type": "DRUG"
        },
        {
          "name": "Treatment C: Emraclidine 30mg IR test tablets 2",
          "type": "DRUG"
        },
        {
          "name": "Treatment D: Emraclidine 30mg IR test tablets 3",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cerevel Therapeutics, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 15,
      "start_date": "2023-07-19",
      "completion_date": "2023-09-12",
      "has_results": false,
      "last_update_posted_date": "2023-11-24",
      "last_synced_at": "2026-09-02T04:21:50.595Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05933187"
    },
    {
      "nct_id": "NCT05935033",
      "title": "A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of Emraclidine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hepatic Impairment"
      ],
      "interventions": [
        {
          "name": "Emraclidine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 38,
      "start_date": "2023-06-30",
      "completion_date": "2025-02-21",
      "has_results": false,
      "last_update_posted_date": "2025-04-04",
      "last_synced_at": "2026-09-02T04:21:50.595Z",
      "location_count": 3,
      "location_summary": "Miami, Florida • Orlando, Florida • San Antonio, Texas",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05935033"
    },
    {
      "nct_id": "NCT04787302",
      "title": "PET Trial to Evaluate Target Occupancy of CVL-231 on Brain Receptors Following Oral Dosing",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Schizophrenia"
      ],
      "interventions": [
        {
          "name": "CVL-231",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cerevel Therapeutics, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 15,
      "start_date": "2021-06-01",
      "completion_date": "2023-07-14",
      "has_results": false,
      "last_update_posted_date": "2023-07-27",
      "last_synced_at": "2026-09-02T04:21:50.595Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04787302"
    },
    {
      "nct_id": "NCT05940402",
      "title": "A Study to Evaluate Pharmacokinetic and Safety Trial of Emraclidine in Participants With Renal Impairment Compared With Participants With Normal Renal Function",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Renal Impairment"
      ],
      "interventions": [
        {
          "name": "Emraclidine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 58,
      "start_date": "2023-07-24",
      "completion_date": "2024-12-19",
      "has_results": false,
      "last_update_posted_date": "2025-04-04",
      "last_synced_at": "2026-09-02T04:21:50.595Z",
      "location_count": 5,
      "location_summary": "Tustin, California • Miami, Florida • Orlando, Florida + 1 more",
      "locations": [
        {
          "city": "Tustin",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Knoxville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05940402"
    },
    {
      "nct_id": "NCT06366243",
      "title": "A Trial to Evaluate the Effect of Esomeprazole on the Pharmacokinetics of Emraclidine in Healthy Adult Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Participants"
      ],
      "interventions": [
        {
          "name": "Emraclidine",
          "type": "DRUG"
        },
        {
          "name": "Esomeprazole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cerevel Therapeutics, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 20,
      "start_date": "2024-05-10",
      "completion_date": "2024-06-20",
      "has_results": false,
      "last_update_posted_date": "2024-07-24",
      "last_synced_at": "2026-09-02T04:21:50.595Z",
      "location_count": 1,
      "location_summary": "Dilworth, Minnesota",
      "locations": [
        {
          "city": "Dilworth",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06366243"
    }
  ]
}